List view / Grid view
26 February 2016 | By Victoria White
New licensed drugs that have been denied access since May 2015 will have to wait until at least July 2016 before they can be considered for the new Cancer Drug Fund...
26 February 2016 | By Victoria White
TAF is a novel, targeted prodrug of tenofovir that has demonstrated high antiviral efficacy similar to Gilead’s Viread at one-tenth of the dose...
Traditional concentration of reverse phase HPLC fractions to dryness in a Genevac HT evaporator is a fast and safe process...
25 February 2016 | By Victoria White
Pooled analysis from the TOMORROW and INPULSIS trials provides further evidence that Ofev (nintedanib) significantly reduces the risk of acute exacerbations by 47% in people...
25 February 2016 | By Victoria White
GBI Research states that Parkinson’s disease market growth will occur despite the patent expiries of several key products during the forecast period...
AstraZeneca and Acerta Pharma have announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted three positive opinions recommending acalabrutinib (ACP-196) for designation as an orphan medicinal product.
25 February 2016 | By Victoria White
The Phase I trial is designed to assess the safety and feasibility of NKR-2, in two different haematological indications...
24 February 2016 | By Victoria White
The osteoarthritis treatment market will experience seismic changes over the next decade, according to a GlobalData analyst...
24 February 2016 | By Victoria White
GlobalData says China will continue to dominate the hepatitis B treatment space, as its market share rises from 38.8% in 2014 to 47.2% by 2024...
24 February 2016 | By Victoria White
Avycaz was first approved in the US in February 2015 for the treatment of adult patients with cIAI and cUTI caused by designated susceptible bacteria...
24 February 2016 | By Tecan
The ARNA Laboratory in Bordeaux, France, is using DNA and RNA aptamers to develop novel tools for biological applications...
24 February 2016 | By Victoria White
This is the first authorisation for necitumumab in Europe and follows US Food and Drug Administration (FDA) approval in November 2015...
24 February 2016 | By Victoria White
At Week 48 of the study, the F/TAF-based regimens were found to be statistically non-inferior to the F/TDF-based regimens in HIV-1 infected adult patients...
24 February 2016 | By Biopharma Group
Liposomes are valued delivery vehicles for potent and efficacious active pharmaceuticals...
24 February 2016 | By CPhI
CPhI Russia @ IPhEB, organised by UBM EMEA, returns for the fourth consecutive year in Russia as business opportunities in the country remain diverse...
